After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement…
This past three months in the Alzheimer’s drug development space have seen a new FDA approval for a symptomatic treatment, a couple failed phase…
In a recent survey, Being Patient put a question to readers: “What is the biggest barrier preventing you from seeking a trial?” The most…
The monoclonal antibody drugs targeting the brain’s amyloid plaques dominated the news cycle in 2023. Eisai and Biogen’s Leqembi was approved by the FDA…